Perbak Capital Partners LLP Purchases Shares of 35,044 10x Genomics $TXG

Key Points

• Perbak Capital Partners LLP invested $306,000 in 10x Genomics by acquiring 35,044 shares as reported in their recent 13F filing with the SEC.
• 10x Genomics reported earnings of $0.28 EPS for the last quarter, significantly exceeding analysts' expectations of ($0.35) and reflecting a year-over-year revenue increase of 12.9%.
• Insider transactions include significant sales by CEO Serge Saxonov and CFO Adam Taich, with the company insiders having sold a total of 39,149 shares valued at approximately $539,865 over the last ninety days.

Perbak Capital Partners LLP purchased a new stake in 10x Genomics (NASDAQ:TXG - Free Report) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 35,044 shares of the company's stock, valued at approximately $306,000.

Several other large investors have also modified their holdings of TXG. GAMMA Investing LLC increased its stake in 10x Genomics by 81.8% during the 1st quarter. GAMMA Investing LLC now owns 3,586 shares of the company's stock worth $31,000 after buying an additional 1,614 shares during the period. Xponance Inc. increased its stake in 10x Genomics by 17.4% during the 1st quarter. Xponance Inc. now owns 12,010 shares of the company's stock worth $105,000 after buying an additional 1,778 shares during the period. GF Fund Management CO. LTD. purchased a new stake in 10x Genomics during the 4th quarter worth $32,000. AlphaQuest LLC increased its stake in 10x Genomics by 8.3% during the 1st quarter. AlphaQuest LLC now owns 29,459 shares of the company's stock worth $257,000 after buying an additional 2,258 shares during the period. Finally, Signaturefd LLC grew its holdings in 10x Genomics by 134.3% during the 1st quarter. Signaturefd LLC now owns 4,203 shares of the company's stock worth $37,000 after acquiring an additional 2,409 shares in the last quarter. 84.68% of the stock is currently owned by institutional investors and hedge funds.

10x Genomics Trading Up 2.9%

NASDAQ:TXG traded up $0.39 during mid-day trading on Friday, hitting $13.96. The stock had a trading volume of 1,875,228 shares, compared to its average volume of 2,782,988. The stock has a market capitalization of $1.74 billion, a price-to-earnings ratio of -19.94 and a beta of 2.00. The company has a 50 day simple moving average of $13.15 and a 200-day simple moving average of $10.75. 10x Genomics has a 52 week low of $6.78 and a 52 week high of $24.38.

10x Genomics (NASDAQ:TXG - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.63. The firm had revenue of $172.91 million for the quarter, compared to the consensus estimate of $139.36 million. 10x Genomics had a negative net margin of 13.13% and a negative return on equity of 12.88%. 10x Genomics's quarterly revenue was up 12.9% compared to the same quarter last year. During the same period last year, the firm posted ($0.32) EPS. 10x Genomics has set its Q3 2025 guidance at EPS. As a group, equities research analysts anticipate that 10x Genomics will post -1.43 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have weighed in on TXG shares. JPMorgan Chase & Co. decreased their price objective on shares of 10x Genomics from $12.00 to $9.00 and set a "neutral" rating for the company in a report on Friday, May 9th. Morgan Stanley decreased their price objective on shares of 10x Genomics from $18.00 to $17.00 and set an "overweight" rating for the company in a report on Tuesday, August 12th. Weiss Ratings reissued a "sell (e+)" rating on shares of 10x Genomics in a report on Saturday, August 30th. UBS Group raised their price objective on shares of 10x Genomics from $12.00 to $13.00 and gave the stock a "neutral" rating in a report on Friday, August 8th. Finally, Canaccord Genuity Group set a $16.00 price objective on shares of 10x Genomics in a report on Monday, August 11th. Six investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, 10x Genomics has an average rating of "Hold" and a consensus target price of $13.54.

Insider Activity at 10x Genomics

In other 10x Genomics news, CEO Serge Saxonov sold 9,348 shares of the business's stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $13.79, for a total transaction of $128,908.92. Following the sale, the chief executive officer directly owned 945,892 shares in the company, valued at approximately $13,043,850.68. The trade was a 0.98% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Benjamin J. Hindson sold 7,486 shares of the company's stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $13.79, for a total value of $103,231.94. Following the completion of the sale, the insider owned 440,888 shares of the company's stock, valued at $6,079,845.52. This trade represents a 1.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 39,149 shares of company stock worth $539,865 in the last ninety days. 9.39% of the stock is owned by insiders.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.